The short version of secretagogue fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Includes two non-natural residues |
| Molecular weight | About 711.9 g/mol | Confirmed by mass spectrometry |
| Appearance | White to off-white powder | Typical lyophilized form |
| Receptor target | GHS-R1a | Ghrelin receptor agonist |
| Plasma half-life | Roughly 2 hours | Varies by species and assay |
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
Purity assessment for this peptide relies mainly on reversed-phase high-performance liquid chromatography. A C18 column with a water-acetonitrile gradient containing trifluoroacetic acid separates the target from truncated sequences and oxidation products. Detection near 214 nm exploits the amide backbone, while the aromatic side chains allow additional monitoring close to 280 nm. Reported purity values depend on the method, so a certificate of analysis carries weight only when gradient, column and integration parameters are given.
Mass spectrometry confirms identity and reveals structural deviations that chromatography alone can miss. Positive-mode electrospray ionisation generally yields multiply charged ions whose deconvoluted mass is checked against the theoretical value. Amino acid analysis, and enzymatic digestion with subsequent fragment mapping, provide independent confirmation of sequence and of the terminal amide. Analysts take care to separate the target from deletion sequences, which may differ by one residue and therefore by only a small mass increment.
The lyophilised solid is normally held at -20 °C or colder, shielded from light and moisture. Stability in that state is measured in years, although shelf life depends on residual water content and the container seal. Once dissolved, the peptide is more fragile: aqueous solutions are commonly kept at 2-8 °C and used within days to weeks, and repeated freeze-thaw cycling is avoided. Strongly acidic or basic conditions accelerate hydrolysis, and prolonged exposure to them can strip the terminal amide.
Codtrace. Archived 1 February 2016 at the Wayback Machine. fishbase.org – Scientific Names for Gadus Fisheries Heritage website, Newfoundland and Labrador (archived) Long term trends in Norwegian cod fisheries – the pioneers Species factsheet on cod from the UK Sea Fish Industry Authority (PDF, 2MB) "Cod" . New International Encyclopedia. 1905.
Biosecurity and Nanoscience Laboratory. Researchers apply advances in nanoscience to develop novel technologies for the detection, identification, and characterization of harmful biological pathogens (viruses, spores, and bacteria) and chemical toxins. Center for Accelerator Mass Spectrometry: LLNL's Center for Accelerator Mass Spectrometry (CAMS) develops and applies a wide range of isotopic and ion-beam analytical tools used in basic research and technology development, addressing a spectrum of scientific needs important to the Laboratory, the university community, and the nation. CAMS is the world's most versatile and productive accelerator mass spectrometry facility, performing more than 25,000 AMS measurement operations per year. High Explosives Applications Facility and Energetic Materials Center: At HEAF, teams of scientists, engineers, and technicians address nearly all aspects of high explosives: research, development and testing, material characterization, and performance and safety tests. HEAF activities support the Laboratory's Energetic Materials Center, a national resource for research and development of explosives, pyrotechnics, and propellants. National Atmospheric Release Advisory Center: NARAC is a national support and resource center for planning, real-time assessment, emergency response, and detailed studies of incidents involving a wide variety of hazards, including nuclear, radiological, chemical, biological, and natural atmospheric emissions.
=== Incidents involving medical radiation sources === A radioactive contamination incident occurred in 1984 in Ciudad Juárez, Chihuahua, Mexico, originating from a radiation therapy unit illegally purchased by a private medical company and subsequently dismantled for lack of personnel to operate it. The radioactive material, 60Co, ended up in a junkyard, where it was sold to foundries that inadvertently smelted it with other metals and produced about 6,000 tons of contaminated rebar. These were distributed in 17 Mexican states and several cities in the United States. It is estimated that 4,000 people were exposed to radiation as a result of this incident. In the Samut Prakan radiation accident in 2000, a disused radiotherapy head containing a 60Co source was stored at an unsecured location in Bangkok, Thailand and then accidentally sold to scrap collectors. Unaware of the danger, a junkyard employee dismantled the head and extracted the source, which remained unprotected for a period of days at the junkyard. Ten people, including the scrap collectors and workers at the junkyard, were exposed to high levels of radiation and became ill. Three junkyard workers later died of their exposure, which was estimated to be over 6 Gy. Afterward, the source was safely recovered by Thai authorities. In December 2013, a truck carrying a disused 111 TBq 60Co teletherapy source from a hospital in Tijuana to a radioactive waste storage center was hijacked at a gas station near Mexico City. The truck was soon recovered, but the thieves had removed the source from its shielding.
Sources: en.wikipedia.org
The concentrations of species containing reagent A are constrained by a condition of mass-balance, that is, the total (or analytical) concentration, which is the sum of all species' concentrations, must be constant. There is one mass-balance equation for each reagent of the type
== In the aquarium == The minimum tank size requirement for the Ember tetras is at least 10 gallons with few live aquarium plants. Ember tetras should be kept in acidic water with a pH near 6.6, and although their native habitat has very soft water, they have adapted quite well to a wide range of hardness (5–17 dGH). The recommended temperature range is 23–29 °C (73–84 °F). Ideally their tank should contain live plants , a darker substrate, and open water for swimming. Ember tetras should be kept in groups of at least 6, though the recommended number is 9–10, in order to promote schooling. They appreciate a heavily planted aquarium ideally with a small area shaded from direct light, and will spend a lot of time swimming through planted areas, which also offer some protection for their fry. Ember tetras will school with other tetras, such as the neon tetra, but may become stressed by the presence of significantly larger fish. These fish swim at the middle level of the aquarium, and they do not feed from the bottom of the tank. Therefore, it is recommended that they are kept with other bottom dwelling fish (such as pygmy corydoras) so that leftover food is then eaten up off the substrate and not left to waste. Ember tetras can be fed a variety of foods, including flake, frozen, and freeze dried food. Small live foods like worms and brine shrimp are also recommended, as they bring out the fish's colors. In a well maintained heavily planted aquarium, ember tetras have been known to live ten years or more.
=== Automated insulin delivery === Tandem introduced Basal-IQ in 2018. The feature used predicted CGM values to suspend insulin delivery when glucose was expected to become low and resumed delivery when values recovered. Control-IQ is a hybrid closed-loop system that uses CGM readings and a model-predictive algorithm to increase, decrease or suspend basal insulin and to deliver automatic correction boluses. Users still program personal therapy settings and normally announce meals. The FDA authorized Control-IQ through the De Novo pathway in December 2019, creating a regulatory category for interoperable automated glycemic controllers. Tandem launched it in the United States in January 2020 as a software update for compatible t:slim X2 pumps. A revised version, Control-IQ+, broadened supported therapy settings and was cleared in 2025 for adults with type 2 diabetes who require insulin. In the United States, Control-IQ+ is used on both the t:slim X2 and Mobi platforms.
Sources: en.wikipedia.org
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.
It binds the same ghrelin receptor but with greater selectivity in functional assays. Preclinical work reports less cortisol and prolactin stimulation at growth-hormone-releasing doses. Those differences are relative, not absolute, and depend on dose and model.
No major regulatory authority has approved it for human therapeutic use. It is sold as a research chemical for laboratory investigation. Clinical status varies by country and is subject to change.
It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.